After months of political resistance, escalating rhetoric and a deadline that threatened to tip into a full-scale trade war, the European Union and the United States have struck a deal.
The EU-US trade agreement — provisionally agreed on 20 May 2026 following framework negotiations that began in July 2025 — was formally backed by EU member states on 27 May. The European Parliament is expected to conduct its final ratification vote between 15 and 18 June, with the regulation entering into force on the day following its publication in the Official Journal of the EU.
For Irish businesses — and for Ireland as a whole, with its extraordinary concentration of US multinational investment, pharmaceutical exports and transatlantic commercial relationships — the implications are significant and, in some cases, still unresolved.
What the Deal Actually Says
The core terms of the agreement are as follows.
The United States will apply a 15 per cent tariff on most EU goods entering the American market. This is the same rate secured by Japan — higher than the 10 per cent baseline that briefly applied from April 2025, but substantially lower than the 30 per cent tariff that President Trump threatened in May 2026 as the negotiations entered their final phase.
The European Union, in return, has committed to eliminating its existing sectoral tariffs on US goods, including the 10 per cent duty on American car imports. The EU has also committed to purchasing 750 billion dollars worth of energy from the United States and facilitating 600 billion dollars in additional US investments.
Steel and aluminium remain subject to a 50 per cent US tariff, with further negotiations expected. The US must reduce derivative steel and aluminium tariffs to 15 per cent or below by 31 December 2026, or the EU is empowered to suspend concessions on targeted American products. The regulation contains a sunset clause — it will cease to apply at the end of 2029 unless renewed.
Why Ireland Is Particularly Exposed
Ireland's position in this deal is more complex than any other EU member state. The Department of Finance described the deal as being "of critical importance to the Irish economy" in documents prepared for Minister Simon Harris. CEPS, the leading European policy think tank, specifically identified Ireland — alongside Germany and Italy — as among the EU countries that will be disproportionately affected by US tariffs given the scale of their exports to the American market.
The reason is structural. Ireland's export economy is dominated by pharmaceutical and life sciences products. Ireland exports approximately €139 billion in pharmaceutical goods annually — making it the world's third largest pharmaceutical exporter and the largest in the EU. The United States is the primary destination for many of those exports.
The deal sets a 15 per cent tariff on pharmaceutical goods — a figure confirmed by the White House. However, a separate US Department of Commerce investigation under Section 232 of the Trade Expansion Act is currently evaluating the national security implications of importing pharmaceuticals. The outcome of that investigation is expected in the coming weeks and could result in pharmaceutical tariffs being set at a rate higher than 15 per cent. This is the most significant unresolved risk in the deal for Irish business.
The Irish Economy Impact — What the Numbers Show
The Department of Finance modelling, published alongside Budget 2026, provides the most authoritative Irish assessment of tariff impact. The scenario modelled assumes US unilateral tariffs of 15 per cent on goods imports from the rest of the world — which is, effectively, what the deal delivers for Ireland.
Under that scenario, modified domestic demand — the Irish economy's most relevant output measure, which strips out the distorting effects of multinational activity — would be around 1.25 per cent below its no-tariff baseline level by 2030. Employment would be approximately 2 per cent lower than in a no-tariff scenario — representing around 60,000 fewer jobs compared to a baseline where tariffs were not introduced.
These are material but manageable figures, assuming the pharmaceutical uncertainty is resolved at 15 per cent. A higher pharmaceutical tariff under Section 232 would significantly worsen the Irish-specific impact.
EU imports to the US to face 15% tariffs: while this is higher than the previous 10% rate, it is substantially below the 30% rate that was threatened and that would have caused severe disruption. The deal provides certainty — and certainty, in trade policy, has significant economic value.
What It Means for the Multinational Sector
The 245,000 people employed in Ireland by US multinational companies — and the €33 billion in corporation tax receipts that largely flow from the same base — are both products of a business environment that depends on open, predictable transatlantic trade.
The deal does not fundamentally alter Ireland's attractiveness as a location for US FDI. Ireland's value proposition — talent, EU access, common law, English language, political stability — is not primarily a function of tariff rates on goods. Most of the US companies based in Ireland are in technology services and pharmaceuticals, and services trade is not covered by this deal.
However, the 15 per cent goods tariff does affect the economics of Irish-based manufacturing operations that export finished pharmaceutical products to the US market — and those operations represent tens of thousands of direct jobs and hundreds of billions in export value.
IDA Ireland is closely monitoring the Section 232 pharmaceutical investigation. The outcome will be the defining data point for the Irish economy in the second half of 2026.
What Irish Businesses Should Do Now
For Irish businesses with US exposure, the deal creates both obligations and opportunities.
The obligation is to update commercial proposals, pricing templates and contracts to reflect the new 15 per cent tariff ceiling and its implications for cost structures. Businesses that export goods directly to the US need to assess the tariff impact on their margins and pricing strategy.
The opportunity lies in the EU's reduction of tariffs on US goods — including industrial machinery and raw materials. Irish businesses that source inputs from the US may find their supply chain costs reduced under the new framework.
PwC Ireland, in its analysis of the deal, recommends businesses reassess long-term sourcing strategy, evaluate nearshoring and dual-sourcing options and invest in compliance capacity to respond to safeguard investigations and leverage treaty dispute mechanisms.
The deal runs until the end of 2029. It is not permanent. Planning for what comes next should begin now.
The Bottom Line
The EU-US trade deal is a compromise — not a triumph and not a disaster. For Ireland, a 15 per cent tariff on pharmaceutical exports is manageable but not painless, and the Section 232 investigation is a risk that has not yet been resolved. The 60,000 jobs and 1.25 per cent MDD impact modelled by the Department of Finance are real numbers with real consequences.
What the deal provides, above all else, is certainty. After eighteen months of escalating trade rhetoric and the persistent threat of tariffs far higher than 15 per cent, Irish businesses can now plan, price and invest with a defined tariff landscape rather than a volatile unknown.
That is worth something. The question is whether it is worth enough.
Business Pulse covers the Irish economy and enterprise. Subscribe to the Business Pulse Network Briefing — every Tuesday and Thursday.